Assessing extracellular vesicle (EV) PD-L1 via liquid biopsy is an attractive non-invasive approach, but its predictive efficacy is confounded by non-tumor-derived EV background. To overcome this limitation, a novel assay selectively captured tumor-derived EVs (TEX) using the tumor-specific glycoantigen TF-Ag-α in serum from 91 NSCLC patients undergoing anti-PD-1 therapy. While baseline levels showed moderate performance (AUC 0.76), dynamic fold changes after the first treatment cycle revealed a ~4.18-fold increase in responders and a ~20% decrease in non-responders. This dynamic on-treatment metric delivered superior predictive power with an AUC of 0.93 (sensitivity 0.95, specificity 0.80), substantially outperforming both total EV PD-L1 and conventional tissue PD-L1.
This study performed integrated genomic, transcriptomic, and DNA methylation profiling on 76 desmoid tumors (DTs), uncovering frequent mutations in chromatin-remodeling genes, notably KMT2C, in addition to the known CTNNB1 and APC mutations. Transcriptomic analysis identified two robust molecular subtypes: immune-myogenic and mesenchymal-like. The immune-myogenic subtype exhibited high expression of myogenic markers and immune checkpoint genes, alongside enhancer hypomethylation. This subtype is associated with increased immune cell infiltration and predicts a higher responsiveness to immune checkpoint inhibitors.
This pooled analysis of two phase II clinical trials, MEDITREME and METIMMOX, investigated the efficacy of first-line chemoimmunotherapy in patients with microsatellite stable (MSS) metastatic colorectal cancer. The findings revealed a significant improvement in median overall survival for the chemoimmunotherapy group compared to chemotherapy alone. Additionally, higher complete response rates were observed with the combination therapy. The study also suggests that baseline CD8+ T-cell infiltration could serve as a predictive biomarker to identify patients most likely to benefit from this treatment approach.
An open-label, phase 3 trial evaluated zanidatamab, a HER2-targeted bispecific antibody, with or without tislelizumab (anti-PD-1), combined with chemotherapy, as first-line treatment for HER2-positive advanced gastroesophageal adenocarcinoma. Patients were randomized to receive zanidatamab-tislelizumab-chemotherapy, zanidatamab-chemotherapy, or trastuzumab-chemotherapy. Both zanidatamab-tislelizumab-chemotherapy and zanidatamab-chemotherapy arms demonstrated significantly longer progression-free survival (median 12.4 months for both) compared to trastuzumab-chemotherapy (8.1 months). Overall survival was also longer with zanidatamab-tislelizumab-chemotherapy (26.4 months) than with trastuzumab-chemotherapy (19.2 months). Diarrhea was the most common grade 3 or higher adverse event.